Array BioPharma Inc (ARRY)

8.98
NASDAQ : Health Care
Prev Close 8.98
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.10 / 13.40
Avg Volume 2.80M
Exchange NASDAQ
Shares Outstanding 171.44M
Market Cap 1.53B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

This Biotech Stock Is Surging More Than 20% Today

This Biotech Stock Is Surging More Than 20% Today

Here are the names.

These Stocks Are Changing Course

These Stocks Are Changing Course

Bullish and bearish reversals for this week.

Biotech Movers: Akari, Array, Amicus

Biotech Movers: Akari, Array, Amicus

Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.

Bristol-Myers Hookup Boosts Array BioPharma

Bristol-Myers Hookup Boosts Array BioPharma

Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.

Despite Amazon's Stock Hitting $1,000, the Nasdaq Is in Danger of Breaking This Streak

Despite Amazon's Stock Hitting $1,000, the Nasdaq Is in Danger of Breaking This Streak

Here's what traders are saying.

Another Drop in Crude Oil Prices Pulls S&P 500 From Records

Another Drop in Crude Oil Prices Pulls S&P 500 From Records

Crude oil prices continue their decline on Tuesday, pulling the energy sector lower and the S&P 500 from its records achieved last week.

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Stock Futures Lower as Traders Return From Long Holiday Weekend

Stock Futures Lower as Traders Return From Long Holiday Weekend

Stock futures point to a lower open on Tuesday as traders return to Wall Street after the long Memorial Day weekend.

Array BioPharma And Bristol-Myers Squibb Announce Strategic Collaboration

Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of...

Array BioPharma And Bristol-Myers Squibb Announce Strategic Collaboration

- Novel combinations of binimetinib, Opdivo® (nivolumab) and Yervoy® (ipilimumab) to be studied in colorectal cancer patients

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.

How Far Into the Drug Pipeline Should the FTC Reach?

How Far Into the Drug Pipeline Should the FTC Reach?

Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

Here's how to potentially rake in some fat profits off a number of hot breakout setups.

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

Here's how to trade six of the most active names on the market this afternoon.

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Biotech Premarket Movers: CytomX, Aevi, Esperion

Biotech Premarket Movers: CytomX, Aevi, Esperion

CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Array BioPharma Provides NEMO Update

- NRAS-mutant melanoma NDA withdrawn based on thorough discussions with FDA and following late cycle review meeting -

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

Jim Cramer is bullish on PaylPal, CH Robinson Worldwide, Texas Instruments and NXP Semiconductors.

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Jim Cramer highlight's Buffett's confidence in American businesses and stocks, and his critique of high fees charged by money managers.

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More

Here are Friday's top research calls, including an upgrade for Ford and downgrades for Eaton, Altria and Ralph Lauren.

Analysts' Actions -- Air Products, Disney, Colgate-Palmolive, Noble and More

Analysts' Actions -- Air Products, Disney, Colgate-Palmolive, Noble and More

Here are Monday's top research calls, including downgrades for Air Products and Colgate-Palmolive, and upgrades for Disney and Noble.

Take-Two Interactive and Actvision Blizzard: 'Mad Money' Lightning Round

Take-Two Interactive and Actvision Blizzard: 'Mad Money' Lightning Round

Jim Cramer thinks Take-Two Interactive and Activision Blizzard have winning potential.

Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)

Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)

The idea of buying American and hiring American is good news for defense, ag and energy stocks, says Jim Cramer.

Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018

Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018

The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.

'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks

'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks

Alaska Air is 'among the best,' says Jim Cramer; he also likes Southwest.

Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq

Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq

How did these technology stocks suddenly get their groove back? asks Jim Cramer.

The Market Offers Some Opportunities but They're Disappearing Fast

The Market Offers Some Opportunities but They're Disappearing Fast

The market isn't buying that Trump is bad for business

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed

Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.